OncoMatch/Clinical Trials/NCT06526104
Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis
Is NCT06526104 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Tremelimumab and Durvalumab for hepatocellular carcinoma.
Treatment: Tremelimumab · Durvalumab — This is a single-arm, phase II study of patients with advanced liver cancer or hepatocellular carcinoma (HCC) who are eligible for first-line treatment with T300+D. The invesitgators hypothesize that T300+D will be safe and tolerated in CP-B patients with HCC. HCC mostly affects disadvantaged populations with higher rates among racial/ethnic minorities, who are often not included in clinical trials (i.e., Hispanics, Blacks, underserved, low socioeconomic status) and present with more severe disease. Given there is not much data in the US patient cohort, this study provides a chance to gain that knowledge.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic therapy
Prior systemic therapy for locally advanced or metastatic HCC
Cannot have received: durvalumab and/or tremelimumab (durvalumab, tremelimumab)
Prior randomisation or treatment in a previous durvalumab and/or tremelimumab clinical study regardless of treatment arm assignment
Lab requirements
Blood counts
Absolute neutrophil counts ≥1000/uL; Platelets ≥60 × 100/uL; Hemoglobin ≥8.0 g/dL
Kidney function
Measured or calculated creatinine clearance >40 mL/min (Cockcroft-Gault or 24-hour urine collection)
Liver function
Child-Pugh-B7 or -B8 liver cirrhosis; ALT and AST ≤5× upper limit of normal each; Bilirubin ≤3 mg/dL; INR ≤2.3 or prothrombin time ≤6 seconds above control
Adequate organ and bone marrow function: Absolute neutrophil counts ≥1000/uL; Platelets ≥60 × 100/uL; Hemoglobin ≥8.0 g/dL; ALT and AST ≤5× upper limit of normal each; Bilirubin ≤3 mg/dL; INR ≤2.3 or prothrombin time ≤6 seconds above control; Measured creatinine clearance (CL) >40 mL/min or Calculated creatinine clearance CL>40 mL/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UT Health San Antonio · San Antonio, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify